drugset / Trial / NCT06364319
Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD
NaSingle-groupOpen-labelTreatment
Summary
The study plan aims to include patients who have been diagnosed with steroid-refractory chronic GVHD in the liver following allogeneic hematopoietic stem cell transplantation. After obtaining informed consent, the patients will receive a treatment regimen consisting of the Anti-CD25 rhMAb in combination with prednisone, cyclosporine, and ruxolitinib.The objective is to assess the effectiveness and safety of Anti-CD25 rhMAb in the treatment of severe chronic GVHD affecting the liver.
Timeline
- Start
- 2026-07-15
- Primary completion
- 2027-12-31
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-CD25 rhMAb | Monoclonal antibody | 1 mg/kg | Intravenous |
| Background | Cyclosporine | Peptide | 1.25 mg/kg | Oral |
| Background | Prednisone | Other / unclassified | — | — |
| Background | Ruxolitinib | Small molecule | 10 mg | Oral |